Trial Profile
Follow-up of the Study 971-ONC-0028-080: "Exemestane Versus Megestrol Acetate In Postmenopausal Patients With Metastatic Breast Cancer, Failing Anti-Estrogens: An Open-Label, Randomized, Parallel-Group, Phase III Comparative Study.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 May 2011
Price :
$35
*
At a glance
- Drugs Exemestane (Primary) ; Megestrol
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Pfizer
- 11 Mar 2011 Actual end date changed from 1 Feb 2010 to 1 Dec 2010 as reported by ClinicalTrials.gov.
- 16 Nov 2010 New trial record